Athira Pharma Presents Preliminary Results from Phase 1 Trial of NDX-1017 at Alzheimer’s Association International Conference 2019 (AAIC)

Athira Pharma Presents Preliminary Results from Phase 1 Trial of NDX-1017 at Alzheimer’s Association International Conference 2019 (AAIC)
SEATTLE, July 16, 2019 /PRNewswire/ -- Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer's and Parkinson's that are focused on regeneration, today announced preliminary data from the Phase 1 clinical trial of its lead therapeutic ... read more
Source: PR NewswirePublished on 2019-07-16